Across TCGA pan-cancer cohorts, PLEKHM1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLEKHM1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PLEKHM1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLEKHM1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and LUAD are the cancer types where PLEKHM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	1.000	0.801	.002	40	view →
LSCC	DFS	Median	II,III,IV	1.000	0.837	.005	11	view →
LUAD	OS	Median	II,III,IV	1.000	0.818	.016	8	view →
GBM	OS	Tertile	All	0.368	0.590	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: PLEKHM1 tumor-vs-normal RNA expression · all PLEKHM1 data types